Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep in 3rd line HR+/HER2 negative breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 17, 2024 10:07am

81 Views

Post# 36227020

RE:RE:RE:RE:RE:RE:RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

That would be great if they could apply for AA by the end of this year. Can u tell me where they said that so I can add it to my library of information. I do know in the recent fireside that I just listened to that kirk stated that they could apply for AA during the new trial but it would be a function of the results at that time and not a given that the fda would accept that. And no where in the fireside did.they mention that they would apply for AA based on the upcoming bracelet os results.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”